Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $10.20.

Several equities research analysts recently weighed in on the company. Guggenheim reaffirmed a "buy" rating on shares of Outlook Therapeutics in a report on Tuesday, May 20th. Chardan Capital restated a "neutral" rating and issued a $3.00 target price on shares of Outlook Therapeutics in a research note on Tuesday, February 18th. HC Wainwright dropped their price target on shares of Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday, February 18th. Finally, Ascendiant Capital Markets cut their price target on shares of Outlook Therapeutics from $33.00 to $24.00 and set a "buy" rating for the company in a report on Monday, February 24th.

Outlook Therapeutics Trading Down 1.0%

Shares of OTLK traded down $0.02 during mid-day trading on Thursday, hitting $1.58. 320,252 shares of the company's stock were exchanged, compared to its average volume of 586,499. Outlook Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $9.25. The business's 50 day moving average is $1.46 and its two-hundred day moving average is $1.97. The firm has a market capitalization of $53.17 million, a P/E ratio of -0.21 and a beta of 0.39.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.15. On average, equities research analysts forecast that Outlook Therapeutics will post -2.27 earnings per share for the current year.

Institutional Investors Weigh In On Outlook Therapeutics

Several institutional investors have recently made changes to their positions in OTLK. Goldman Sachs Group Inc. increased its holdings in shares of Outlook Therapeutics by 74.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock valued at $126,000 after purchasing an additional 44,063 shares in the last quarter. AQR Capital Management LLC increased its holdings in Outlook Therapeutics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock valued at $103,000 after buying an additional 25,351 shares in the last quarter. Jane Street Group LLC increased its holdings in Outlook Therapeutics by 133.9% in the fourth quarter. Jane Street Group LLC now owns 26,218 shares of the company's stock valued at $50,000 after buying an additional 15,008 shares in the last quarter. Scotia Capital Inc. lifted its position in shares of Outlook Therapeutics by 124.4% during the 4th quarter. Scotia Capital Inc. now owns 73,989 shares of the company's stock valued at $140,000 after acquiring an additional 41,023 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in shares of Outlook Therapeutics during the 4th quarter worth approximately $246,000. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.